Lia Luus

938 total citations
24 papers, 649 citations indexed

About

Lia Luus is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lia Luus has authored 24 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lia Luus's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and Immunotherapy and Immune Responses (4 papers). Lia Luus is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and Immunotherapy and Immune Responses (4 papers). Lia Luus collaborates with scholars based in United States and Canada. Lia Luus's co-authors include Yuhong Guo, Amarnath Natarajan, José A. Halperin, Hüseyin Aktaş, Charlotte F. McDonagh, Arthur J. Kudla, Violette Paragas, Michael Chorev, Han Chen and Alexandra Huhalov and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and American Journal Of Pathology.

In The Last Decade

Lia Luus

24 papers receiving 634 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lia Luus United States	10	259	247	239	206	71	24	649
Heidi L. Perez United States	6	211 0.8×	220 0.9×	235 1.0×	88 0.4×	46 0.6×	9	449
Hari Krishna R. Santhapuram United States	15	333 1.3×	129 0.5×	234 1.0×	222 1.1×	27 0.4×	21	694
Raffaele Colombo Italy	16	321 1.2×	153 0.6×	206 0.9×	220 1.1×	34 0.5×	33	652
Paul J. Kleindl United States	14	378 1.5×	111 0.4×	214 0.9×	207 1.0×	31 0.4×	19	697
Christine Fazenbaker United States	18	310 1.2×	301 1.2×	218 0.9×	70 0.3×	65 0.9×	24	708
Philippe Auzeloux France	15	187 0.7×	219 0.9×	149 0.6×	93 0.5×	51 0.7×	43	509
Sabrina Trüssel Switzerland	7	353 1.4×	294 1.2×	149 0.6×	184 0.9×	16 0.2×	7	578
Jonathan D. Bargh United Kingdom	9	452 1.7×	549 2.2×	597 2.5×	260 1.3×	53 0.7×	9	1.0k
Rita M. Steeves United States	6	237 0.9×	298 1.2×	327 1.4×	74 0.4×	183 2.6×	10	643
Luke A. Masterson United Kingdom	16	355 1.4×	397 1.6×	577 2.4×	286 1.4×	68 1.0×	30	856

Countries citing papers authored by Lia Luus

Since Specialization

Citations

This map shows the geographic impact of Lia Luus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lia Luus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lia Luus more than expected).

Fields of papers citing papers by Lia Luus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lia Luus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lia Luus. The network helps show where Lia Luus may publish in the future.

Co-authorship network of co-authors of Lia Luus

This figure shows the co-authorship network connecting the top 25 collaborators of Lia Luus. A scholar is included among the top collaborators of Lia Luus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lia Luus. Lia Luus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Upadhyaya, Punit, Johanna Lahdenranta, Jun Ma, et al.. (2022). Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. Journal of Medicinal Chemistry. 65(14). 9858–9872. 11 indexed citations

Krumpoch, Megan, Huidong Chen, Lia Luus, et al.. (2022). 834 Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood. Regular and Young Investigator Award Abstracts. A871–A871. 1 indexed citations

Guffroy, Magali, Bruce A. Trela, Lukasz Stawski, et al.. (2022). Selective inhibition of integrin αvβ6 leads to rapid induction of urinary bladder tumors in cynomolgus macaques. Toxicological Sciences. 191(2). 400–413. 3 indexed citations

Reszka-Blanco, Natalia, Vinod Yadav, Megan Krumpoch, et al.. (2021). Abstract 1559: Inhibition of integrin αvβ8 enhances immune checkpoint induced anti-tumor immunity by acting across immunologic synapse in syngeneic models of breast cancer. Cancer Research. 81(13_Supplement). 1559–1559. 1 indexed citations

Kamoun, Walid S., Elden P. Swindell, Christine Pien, et al.. (2020). Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics. 12(10). 996–996. 11 indexed citations

Kamoun, Walid S., Anne‐Sophie Dugast, James Suchy, et al.. (2019). Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. Molecular Cancer Therapeutics. 19(1). 270–281. 15 indexed citations

Dumont, Nancy, Cynthia Lavoie, Vasilios Papavasiliou, et al.. (2019). Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment. Nanomedicine Nanotechnology Biology and Medicine. 17. 71–81. 27 indexed citations

Koshkaryev, Alexander, Ozan Alkan, Lia Luus, et al.. (2019). Abstract 8: Targeting DNA-damage response pathway with a novel nano-liposomal ATR inhibitor in solid tumors. 8–8. 1 indexed citations

Fulton, Ross B., Jennifer Richards, Christina S.F. Wong, et al.. (2019). Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity. Cancer Research. 79(13_Supplement). 3270–3270. 1 indexed citations

10.

Kamoun, Walid S., Lia Luus, Christine Pien, et al.. (2016). Abstract 871: Nanoliposomal targeting of ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale. Cancer Research. 76(14_Supplement). 871–871. 2 indexed citations

11.

Drummond, Daryl C., Michael T. Moser, Walid S. Kamoun, et al.. (2016). Abstract 2069: Activity of an EphA2-targeted docetaxel nanoliposome in pancreatic patient-derived models as monotherapy and in combination with gemcitabine. Cancer Research. 76(14_Supplement). 2069–2069. 1 indexed citations

12.

Onsum, Matthew, Elena Geretti, Violette Paragas, et al.. (2013). Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients. American Journal Of Pathology. 183(5). 1446–1460. 72 indexed citations

13.

McDonagh, Charlotte F., Alexandra Huhalov, Brian D. Harms, et al.. (2012). Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3. Molecular Cancer Therapeutics. 11(3). 582–593. 222 indexed citations

14.

Geretti, Elena, Violette Paragas, Matthew Onsum, et al.. (2012). Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis. Cancer Research. 72(24_Supplement). P1–7. 2 indexed citations

15.

Huhalov, Alexandra, Sharlene Adams, Violette Paragas, et al.. (2010). Abstract 3485: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit. Cancer Research. 70(8_Supplement). 3485–3485. 4 indexed citations

16.

Nielsen, Ulrik B., Alexandra Huhalov, Brian D. Harms, et al.. (2009). MM-111: a novel bispecific antibody targeting ErbB3 with potent anti-tumor activity in ErbB2 over-expressing malignancies.. Cancer Research. 69(2_Supplement). 4166–4166. 6 indexed citations

17.

Luus, Lia, et al.. (2004). Disruption of membrane cholesterol stimulates MyD88-dependent NF-κB activation in immature B cells. Cellular Immunology. 229(1). 68–77. 13 indexed citations

18.

Youd, Michele, Lia Luus, & Ronald B. Corley. (2004). IgM monomers accelerate disease manifestations in autoimmune-prone Fas-deficient mice. Journal of Autoimmunity. 23(4). 333–343. 4 indexed citations

19.

Chen, Han, Amarnath Natarajan, Yuhong Guo, et al.. (2004). Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorganic & Medicinal Chemistry Letters. 14(21). 5401–5405. 52 indexed citations

20.

Li, J., Eva J. Helmerhorst, Ronald B. Corley, et al.. (2003). Characterization of the immunologic responses to human in vivo acquired enamel pellicle as a novel means to investigate its composition. Oral Microbiology and Immunology. 18(3). 183–191. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact